Full Text Full Text (PDF) Data Supplement Alert me when this article is cited Alert me if a correction is posted Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Kern, R. S. Articles by Marder, S. R. Search for Related Content PubMed Citation Articles by Kern, R. S. Articles by Marder, S. R. Schizophrenia Spectrum Disorders Epidemiology Related Articles

The MATRICS Consensus Cognitive Battery, Part 2: Co-Norming and Standardization

OBJECTIVE: The consensus cognitive battery developed by the National Institute of Mental Health’s (NIMH’s) Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative includes 10 independently developed tests that are recommended as the standard battery for clinical trials of cognition-enhancing interventions for schizophrenia. To facilitate interpretation of results from the MATRICS Consensus Cognitive Battery using a common scaling across tests, normative data were obtained from a single representative U.S. community sample with the battery administered as a unit. METHOD: The MATRICS Consensus Cognitive Battery was administered to 300 individuals from the general community at five sites in differing geographic regions. For each site, recruitment was stratified by age, gender, and education. A scientific survey sampling method was used to help avoid sampling bias. The battery was administered in a standard order to each participant in a single session lasting approximately 60 minutes. Descriptive data were generated, and age, gender, and education effects on performance were examined. RESULTS: Prominent age and education effects were observed across tests. The results for gender differed by measure, suggesting the need for age and gender corrections in clinical trials. The MATRICS Consensus Cognitive Battery components were co-normed, with allowance for demographic corrections. CONCLUSIONS: Co-norming a battery such as the MATRICS Consensus Cognitive Battery, comprising tests from independent test developers each with their own set of norms, facilitates valid interpretation of test scores and communication of findings across studies. These normative data will aid in estimating the magnitude of change during clinical trials of cognition-enhancing agents and make it possible to derive more directly interpretable composite scores.

Related Articles:

Pharmacological Treatment of Cognition in Schizophrenia: An Idea Whose Method Has Come

Philip D. Harvey and Barbara A. Cornblatt
Am J Psychiatry 2008 165: 163-165. [Full Text] [PDF]

This article has been cited by other articles:

				R. Freedman, A. Olincy, R. W. Buchanan, J. G. Harris, J. M. Gold, L. Johnson, D. Allensworth, A. Guzman-Bonilla, B. Clement, M. P. Ball, et al. Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia Am J Psychiatry, August 1, 2008; 165(8): 1040 - 1047. [Abstract] [Full Text] [PDF]

				C. O. SIU Interpreting T Scores and Percentile Equivalents Using the MATRICS Consensus Cognitive Battery in Schizophrenia Trials Am J Psychiatry, July 1, 2008; 165(7): 914 - 914. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2008 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us